Radio-labeled Nanoparticles for Biomedical Imaging - Nanotechnology for Biomedical Imaging and Diagnostics - page 206

nanoprobes showed optimized pharmacokinetics (blood and tumor half-lives = 5.9
and 73.5 h, respectively), α v β 3 -specific tumor uptake, and high tumor-to-muscle
ratio (T/m = 5 at 24 h p.i.). Dosimetry studies demonstrated comparable radiation
doses to other clinically used peT tracers. Toxicity studies confirmed full clearance
in one week and no tissue-specific pathologic effect. A human clinical trial has been
planned to investigate the potential of this targeted nanoprobe in staging metastatic
disease [32].

7.5 summaRy

Radiolabeled nanoparticles have been widely used in biomedical research for drug
delivery and diagnostic imaging. Compared to conventional small-molecule-based
imaging probes, these nanoagents often provided superior pharmacokinetics, enhanced
targeting efficiency, improved biocompatibility, and reduced toxicity, leading to
significant progress in the development of personalized nanomedicine. However,
owing to the complexity of living biological system, nanomedicine is still at the initial
stage toward the future regular clinical application. more effort will need to be focused
on the development of more sensitive and specific nanoagents for the detection of low-
abundant biomarkers at the early stages of disease. furthermore, the translational
potential of these nanoagents must be considered and evaluated for the design of the
nanostructures to be used in future clinical studies.

RefeReNces

[1] börjesson pKe, Jauw YWS, de bree R, Roos JC, Castelijns JA, Leemans CR, van
Dongen gAmS, boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal
antibody U36 as used for immuno-peT in head and neck cancer patients. J Nucl med
2009; 50 :1828-1836.
[2] braun S, Hepp f, Kentenich CRm, Janni W, pantel K, Riethmüller g, Willgeroth f,
Sommer HL. monoclonal antibody therapy with edrecolomab in breast cancer patients:
monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Clin Cancer Res 1999; 5 :3999-4004.
[3] Wolterink S, moldenhauer g, fogel m, Kiefel H, pfeifer m, Lüttgau S, gouveia R, Costa
J, endell J, moebius U, Altevogt p. Therapeutic antibodies to human L1CAm: functional
characterization and application in a mouse model for ovarian carcinoma. Cancer Res
2010; 70 :2504-2515.
[4] Dharap SS, Wang Y, Chandna p, Khandare JJ, Qiu b, gunaseelan S, Sinko pJ, Stein S,
farmanfarmaian A, minko T. Tumor-specific targeting of an anticancer drug delivery
system by LHRH peptide. proc Natl Acad Sci U S A 2005; 102 :12962-12967.
[5] froidevaux S, eberle AN. Somatostatin analogs and radiopeptides in cancer therapy.
pept Sci 2002; 66 :161-183.
[6] Ko SY, guo H, barengo N, Naora H. Inhibition of ovarian cancer growth by a tumor-
targeting peptide that binds eukaryotic translation initiation factor 4e. Clin Cancer Res
2009; 15 :4336-4347.